Mallinckrodt and Endo, drugmakers with a shared history of facing bankruptcy and U.S. opioid litigation, have agreed to merge ...
Mallinckrodt and Endo are exploring a potential merger that could be valued at about $7 billion, person familiar with the ...
Mallinckrodt and Endo are merging in a cash and stock deal worth some $6.7 billion, the companies said Thursday. Under the ...
Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people ...
Endo shareholders will get $80 million in cash and own 49.9 per cent of the combined company, while Mallinckrodt shareholders ...
Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments.
The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in ...
Malvern-based Endo has found a merger partner, agreeing to combine with another troubled pharmaceutical firm in a deal valued ...